May 12th 2025
Newron Pharmaceuticals launches pivotal ENIGMA-TRS trials for evenamide, targeting treatment-resistant schizophrenia with promising efficacy and safety outcomes.
Cobenfy as Add-On Treatment for Schizophrenia Fails to Meet Primary Endpoint in Phase 3 ARISE Trial
April 22nd 2025Cobenfy as an adjunctive treatment to atypical antipsychotics did not reach the primary endpoint of the phase 3 ARISE trial, or a statistically significant difference compared with placebo with an atypical antipsychotic.
Read More
Additional Positive Data on LB-102 for the Treatment of Acutely Exacerbated Schizophrenia
March 31st 2025LB Pharmaceuticals presented additional positive data from NOVA1 exploring LB-102 in patients with acutely exacerbated schizophrenia, at the 2025 Annual Congress of the Schizophrenia International Research Society.
Read More
Phase 1 Study Initiated: NBI-1140675 for Neurological and Neuropsychiatric Conditions
March 5th 2025Neurocrine Biosciences has initiated a phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of NBI-1140675 for certain neurological and neuropsychiatric conditions, such as tardive dyskinesia.
Read More
SPN-820 Fails to Meet Primary Endpoint in Study of Adults with Treatment-Resistant Depression
February 20th 2025After a lot of recent positive news for SPN-820, a recent phase 2b study shows the novel antidepressant failed to demonstrate a statistically significant improvement on the primary endpoint of change from baseline.
Read More
Xanomeline-Trospium as a Novel Agent for Treatment of Psychosis in Schizophrenia
Recent research demonstrated that xanomeline-trospium is more efficacious than placebo in treating positive and negative psychotic symptoms in adults with schizophrenia.
Read More